<p>Subjects having elevated signaling of a mammalian target of rapamycin (mTOR) are treated with compositions that include at least one compound that activates a Group 1 mGluR. In an embodiment, the subject has tuberous sclerosis complex (TSC). In an embodiment, the compound is a Group 1 mGluR agonist. In another embodiment, the compound is a Group 1 mGluR positive allosteric modulator.</p>
申请公布号
WO2011056849(A1)
申请公布日期
2011.05.12
申请号
WO2010US55268
申请日期
2010.11.03
申请人
MASSACHUSETTS INSTITUTE OF TECHNOLOGY;BEAR, MARK, F.;AUERBACH, BENJAMIN, DAVID